Heteroleptic Ir Complex for Saturated OLED Color Emission
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current organic light-emitting diode (OLED) technologies face challenges in achieving saturated colors, particularly in red, green, and blue emissions, which are essential for full-color displays, and existing materials may not efficiently meet the requirements for cost-effectiveness and flexibility.
Innovation Solution
A heteroleptic compound with the Formula Ir(LA)m(LB)3-m is developed, featuring a specific structure that includes monocyclic and polycyclic aromatic rings, with various substituents, allowing for the formation of rings and differing ligands, which is used in OLEDs to enhance color emission properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Illumination intensity
If conventional materials are used in OLEDs, then device fabrication is simplified, but saturated color emission cannot be achieved
Solution Approach 1:
The patent modifies the chemical structure parameters of the emissive material by incorporating specific heterocyclic ligands (LA and LB) with defined aromatic ring structures and substituent groups. This structural parameter change enables the Ir complex to emit saturated red, green, or blue light while maintaining reasonable device fabrication complexity
Solution Approach 2:
The patent creates a composite emissive material by combining the Ir metal center with two different types of ligands (LA and LB) in a heteroleptic complex. This composite structure allows tuning of emission color to achieve saturated colors while the modular ligand design keeps the overall complexity manageable
2Productivity
If existing OLED materials are used, then production costs are reduced, but emission efficiency for saturated colors is insufficient
Solution Approach 1:
The patent optimizes the ligand structure parameters (aromatic ring systems, substituent positions, and types) to enhance the photophysical properties of the Ir complex. This enables high emission efficiency for saturated colors while the synthetic route remains compatible with existing manufacturing processes, controlling production costs
3Adaptability or versatility
If conventional OLED materials are used, then device flexibility is limited, but cost-effective fabrication is achieved
Solution Approach 1:
The patent designs a universal heteroleptic Ir complex structure (Ir(LA)m(LB)3-m) where the ligand framework can be systematically modified to achieve different emission colors (red, green, blue). This multi-functional platform allows the same base structure to be adapted for various applications while maintaining cost-effective fabrication through standardized synthetic approaches
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound improves the emission characteristics of OLEDs, enabling the production of saturated colors and potentially reducing production costs while offering flexibility in device fabrication, thus addressing the limitations of existing OLED technologies.
Implementation Method 1
OLEDs make use of thin organic films that emit light when voltage is applied across the device
Implementation Method 2
One application for phosphorescent emissive molecules is a full color display
Data Source
AI summary
A heteroleptic compound having a Formula Ir(LA)m(LB)3-m, having a structure of Formula Iis disclosed. In Formula I, m is 1 or 2; moieties A, C, and D are each independently monocyclic rings or polycyclic fused ring structures; each R1, R2, RA, RB, RC, RD, and RE is independently hydrogen or a substituent; if moiety A is a monocyclic 6-membered ring, then the RA para to N of ring A is not an aryl group; at least one of R1 and R2 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, and combinations thereof; and adjacent substituents can be joined to form a ring. OLEDs, consumer products, and formulations including the heteroleptic compound are also disclosed.